KTX-1001 is under clinical development by K36 Therapeutics and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KTX-1001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KTX-1001 is under development for the treatment of relapsed and refractory multiple myeloma. The therapeutic candidate targets multiple myeloma set domain containing protein (MMSET, NSD2 and WHSC1). It is administered through oral route.
K36 Therapeutics overview
K36 Therapeutics, a biotechnology company that aims to translate epigenetic modulation of oncogenic pathways into small-molecule treatments. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of KTX-1001’s drug-specific PTSR and LoA scores, buy the report here.